AI English summary of an SEC filing — figures as filed
Bristol Myers Squibb BMYBristol Myers Squibb said its wholly-owned Irish subsidiary BMS Ireland Capital Funding Designated Activity Company completed on November 10, 2025 a public offering of 5 series of euro-denominated notes maturing in 2030, 2033, 2038, 2045 and 2055. The notes are fully and unconditionally guaranteed by the company on a senior unsecured basis.
Key points
AI summaryBristol Myers Squibb said its wholly-owned Irish subsidiary BMS Ireland Capital Funding Designated Activity Company completed on November 10, 2025 a public offering of 5 series of euro-denominated notes maturing in 2030, 2033, 2038, 2045 and 2055. The notes are fully and unconditionally guaranteed by the company on a senior unsecured basis.
Bristol Myers Squibb said it issued the notes as €750,000,000 (2.973%) maturing in 2030, €1,150,000,000 (3.363%) maturing in 2033, €1,150,000,000 (3.857%) maturing in 2038, €750,000,000 (4.289%) maturing in 2045 and €1,200,000,000 (4.581%) maturing in 2055.
The company said it intends to use the net proceeds of the offering, together with approximately $3.0 billion of cash on hand, to fund its tender offer to purchase various series of outstanding notes and other repurchase, repayment or redemption of the notes, to pay related fees and expenses, and to the extent of any remaining proceeds, for general corporate purposes.
Bristol Myers Squibb said interest on the notes is payable annually beginning on November 10, 2026 and on November 10 of each year thereafter, and the make-whole spread by series ranges from +10 basis points for the 2030 notes to +20 basis points for the 2055 notes. The company said the offering was conducted pursuant to an underwriting agreement dated November 5, 2025.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Public offering of 5 series of euro-denominated notes completed
Bristol Myers Squibb said its wholly-owned Irish subsidiary BMS Ireland Capital Funding Designated Activity Company completed on November 10, 2025 a public offering of 5 series of euro-denominated notes maturing in 2030, 2033, 2038, 2045 and 2055. The notes are fully and unconditionally guaranteed by the company on a senior unsecured basis.
Source · Based on the filing body and exhibits
Issuance size and interest rate by series
Bristol Myers Squibb said it issued the notes as €750,000,000 (2.973%) maturing in 2030, €1,150,000,000 (3.363%) maturing in 2033, €1,150,000,000 (3.857%) maturing in 2038, €750,000,000 (4.289%) maturing in 2045 and €1,200,000,000 (4.581%) maturing in 2055.
Source · Based on the filing body and exhibits
Use of net proceeds and cash on hand
The company said it intends to use the net proceeds of the offering, together with approximately $3.0 billion of cash on hand, to fund its tender offer to purchase various series of outstanding notes and other repurchase, repayment or redemption of the notes, to pay related fees and expenses, and to the extent of any remaining proceeds, for general corporate purposes.
Source · Based on the filing body and exhibits
Interest payment schedule and make-whole spread
Bristol Myers Squibb said interest on the notes is payable annually beginning on November 10, 2026 and on November 10 of each year thereafter, and the make-whole spread by series ranges from +10 basis points for the 2030 notes to +20 basis points for the 2055 notes. The company said the offering was conducted pursuant to an underwriting agreement dated November 5, 2025.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…